Segall Bryant & Hamill LLC Trims Stock Holdings in Encompass Health Corporation $EHC

Segall Bryant & Hamill LLC lessened its stake in shares of Encompass Health Corporation (NYSE:EHC) by 28.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 127,903 shares of the company’s stock after selling 50,200 shares during the quarter. Segall Bryant & Hamill LLC owned approximately 0.13% of Encompass Health worth $16,246,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Citizens National Bank Trust Department purchased a new stake in shares of Encompass Health during the third quarter worth about $26,000. First Horizon Corp acquired a new stake in Encompass Health during the third quarter worth approximately $34,000. Westside Investment Management Inc. grew its stake in Encompass Health by 56.7% in the 3rd quarter. Westside Investment Management Inc. now owns 279 shares of the company’s stock worth $35,000 after acquiring an additional 101 shares during the period. Assetmark Inc. raised its holdings in Encompass Health by 88.1% in the 3rd quarter. Assetmark Inc. now owns 299 shares of the company’s stock valued at $38,000 after acquiring an additional 140 shares during the last quarter. Finally, Root Financial Partners LLC purchased a new position in shares of Encompass Health during the 3rd quarter worth $39,000. 97.25% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Barclays lifted their price objective on Encompass Health from $150.00 to $153.00 and gave the company an “overweight” rating in a research report on Friday, February 6th. Wall Street Zen upgraded Encompass Health from a “hold” rating to a “buy” rating in a report on Sunday, January 18th. Finally, Zacks Research downgraded shares of Encompass Health from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 19th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $143.29.

Insider Buying and Selling at Encompass Health

In related news, CEO Mark J. Tarr sold 150,000 shares of the company’s stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $111.64, for a total transaction of $16,746,000.00. Following the completion of the sale, the chief executive officer directly owned 377,070 shares of the company’s stock, valued at approximately $42,096,094.80. This represents a 28.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.10% of the company’s stock.

Encompass Health Price Performance

EHC stock opened at $107.94 on Wednesday. The company has a market cap of $10.73 billion, a PE ratio of 19.48, a price-to-earnings-growth ratio of 2.07 and a beta of 0.71. The company has a current ratio of 1.08, a quick ratio of 1.08 and a debt-to-equity ratio of 0.76. The stock has a 50-day moving average price of $103.89 and a two-hundred day moving average price of $113.88. Encompass Health Corporation has a 12-month low of $92.53 and a 12-month high of $127.99.

Encompass Health (NYSE:EHC) last released its quarterly earnings data on Thursday, February 5th. The company reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.29 by $0.17. The company had revenue of $3.09 billion for the quarter, compared to the consensus estimate of $1.54 billion. Encompass Health had a return on equity of 18.20% and a net margin of 9.54%.The company’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period last year, the business posted $1.17 EPS. Encompass Health has set its FY 2026 guidance at 5.810-6.100 EPS. As a group, research analysts predict that Encompass Health Corporation will post 4.8 EPS for the current year.

Encompass Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 15th. Stockholders of record on Wednesday, April 1st will be paid a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, April 1st. Encompass Health’s dividend payout ratio (DPR) is currently 13.72%.

About Encompass Health

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.